Novo Nordisk A/S (NONOF)
| Market Cap | 313.40B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | n/a |
| EPS (ttm) | 3.40 |
| PE Ratio | 20.68 |
| Forward PE | 17.08 |
| Dividend | 1.66 (2.36%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 300 |
| Average Volume | 136,544 |
| Open | 70.35 |
| Previous Close | 70.18 |
| Day's Range | 69.55 - 72.05 |
| 52-Week Range | 55.28 - 149.55 |
| Beta | 0.22 |
| RSI | 45.55 |
| Earnings Date | Aug 6, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth darling Hims & Hers Health Inc (NYSE: HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE: NVO) ended their relationship – and it wasn't amicable. But is the plunge...
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
Novo Nordisk gets EU backing for Ozempic label expansion
Hims & Hers Health: Significant Impact Of Partnership Termination With Novo Nordisk; Initiate With 'Sell'
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' ...
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug target...
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch
Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.
Novo Nordisk launches blockuster weight-loss drug Wegovy in India
Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week injection in India.
Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its blockbuster drug Wegovy.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an up...
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
On Monday, HC Wainwright initiated coverage on Septerna, Inc. (NASDAQ: SEPN), citing a next-generation drug design platform aimed at hitherto-undruggable targets . Septerna is working on G protein-co...
Why Novo Nordisk Stock Is Sinking Today
Novo Nordisk ends partnership with Hims & Hers over Wegovy copycats
Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, citing deceptive marketing and the selling of knock-off versions of its blockbus...
Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday?
Wall Street showed unexpected resilience Monday as investors looked past a sharp escalation in the Middle East, where Iran fired missiles at U.S. military bases in Qatar and Iraq — just 48 hours after...
Novo Nordisk Ends Partnership with Hims & Hers
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility
Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see approach for both NVO and HIMS.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2212016083-0d16f59172f24adf9ec2eec0a1e754ab.jpg)
Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
Hims & Hers Health shares tumbled 30% in intraday trading Monday after Novo Nordisk said it is pulling out of its partnership with the digital pharmacy, citing "illegal" and "deceptive" practices.
Stocks making the biggest moves midday: Tesla, Novo Nordisk, Hims & Hers, Northern Trust, Fiserv and more
These are the stocks posting the largest moves in midday trading.